Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
Summary
Agios presented detailed Phase 3 RISE UP data for mitapivat at the EHA 2026 plenary session. The results showed statistically significant hemoglobin improvement versus placebo and a meaningful reduction in transfusion burden. Patients who achieved hemoglobin response also saw better outcomes for pain crises, fatigue, sleep, and physical function. Agios reiterated that mitapivat was well tolerated and noted its recent sNDA submission for sickle cell disease in the U.S.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected